Table 1.
Baseline patient and treatment characteristics
| Characteristics | N = 20 | % |
|---|---|---|
| Age | ||
| Median (range), in years | 76 (66-83) | |
| ISUP group before the primary treatment | ||
| 1 | 5 | 25 |
| 2 | 6 | 30 |
| 3 | 3 | 15 |
| 4 | 3 | 15 |
| 5 | 2 | 10 |
| Unknown | 1 | 5 |
| Primary treatment | ||
| EBRT or EBRT + ADT | 15 | 75 |
| Brachytherapy | 2 | 10 |
| Prostatectomy + EBRT | 3 | 15 |
| Irradiation dose (Gy) delivered during the primary treatment | ||
| 66 | 2 | 10 |
| 70 | 1 | 5 |
| 74 | 8 | 40 |
| 76 | 1 | 5 |
| 78 | 2 | 10 |
| 80 | 4 | 20 |
| 160 (LDR brachytherapy) | 2 | 10 |
| Primary irradiation areas | ||
| Prostate alone | 12 | 60 |
| Prostate + pelvis | 5 | 25 |
| Prostate bed alone | 1 | 5 |
| Prostate bed + pelvis | 2 | 10 |
| Median interval between primary treatment and MRgRT (range), in months | 123.5 (21-252) | |
| ECOG score before MRgRT | ||
| 0 | 11 | 55 |
| 1 | 9 | 45 |
| PSA concentration (μg/mL) before MRgRT | ||
| Median (range) | 3.7 (0.34-34.7) | |
| Dysuria before MRgRT | ||
| Grade 0 | 16 | 80 |
| Grade 1 | 2 | 10 |
| Grade 2 | 2 | 10 |
| IPSS score and symptom groups before MRgRT | ||
| Median score (range) | 3 (1-33) | 70 |
| Mild (1-7) | 14 | 20 |
| Moderate (8-19) | 4 | 10 |
| Severe (20-35) | 2 | |
| Dose prescription for MRgRT | ||
| 27.5 Gy/5 fractions | 5 | 25 |
| 30 Gy/5 fractions | 12 | 60 |
| 30 Gy/6 fractions | 2 | 10 |
| 38.7 Gy/9 fractions | 1 | 5 |
| Concomitant ADT during MRgRT | ||
| Yes | 4 | 20 |
| No | 16 | 80 |
Abbreviations: ADT = androgen deprivation therapy; EBRT = external beam radiation therapy; ECOG = Eastern Cooperative Oncology Group; IPSS = international prostate symptom score; ISUP = international society of urologic pathology; LDR = low-dose rate; MRgRT = magnetic resonance-guided adaptive radiation therapy; PSA = prostate-specific antigen.